Form D · Biotechnology

Enterin, Inc.

Philadelphia, PA · CIK 0001711351

Offering snapshot reported Dec 6, 2023 · SEC filing

Reported sold
$5.1M
Offering amount: $20M
Investors reported
4
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 21, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 6, 2023Initial$5,099,772No comparison4SEC filing
Sep 12, 2022Initial$6,000,000No comparison3SEC filing
Oct 8, 2021Initial$5,685,438No comparison2SEC filing
Sep 16, 2020Initial$11,703,493No comparison9SEC filing
Jan 28, 2019Initial$16,699,970No comparison6SEC filing
Jul 14, 2017Initial$5,467,272No comparison21SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-498925

Source: Form D, filed Dec 6, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Denise Barbut Director, Executive
Stuart Barlow Executive
Jay A Brammer Director
Mark Finn Director
William Kinney Executive
Richard Larson Executive
David Mc Cullough Director, Executive
Barry Miller Director
Roger Mills Director
Don Munoz Director
Nancy Ness Executive
Richard Propper Director
David Vogel Director
Katherine Wolf Executive
Michael Zasloff Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
2005 Market Street Suite 3125
Philadelphia, PA, 19103